# US 2026/0097150 A1 · Implantable Device for Treating an Ocular Condition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097150 A1
- Document ID: US20260097150A1
- Status: Published application
- Kind: A1
- Application number: 19/348,856
- Filed: 2025-10-03
- Published: 2026-04-09
- Earliest claimed: 2024-10-07
- Assignees: Celanese EVA Performance Polymers LLC
- Applicants: Celanese EVA Performance Polymers LLC
- Inventors: Harsh Patel; Jeffrey Haley; Cyonna Holmes
- Web page: https://patentgrep.com/patent/US20260097150A1

## CPC

- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 2300/222: Steroids, e.g. corticosteroids
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

The implantable device includes a core including a core polymer matrix within which is dispersed one or more therapeutic agents. The core polymer matrix includes a hydrophobic polymer comprising a first poly ortho ester (POE) polymer. The POE polymer has a Tg of between about −20° C. and 40° C. as determined in accordance with ASTM E1640-18. Methods for treating conditions in a patient in need thereof are also provided.

## Claims

### Claim 1

An implantable device for ocular insertion, the implantable device comprising: a core comprising a core polymer matrix within which is dispersed one or more therapeutic agents, wherein core polymer matrix comprises a hydrophobic polymer comprising a first poly ortho ester (POE) polymer, wherein the POE polymer has a Tg of between about −20° C. and 40° C. as determined in accordance with ASTM E1640-18.

### Claim 2 (depends on 1)

The implantable device of claim 1, wherein the one or more therapeutic agents constitute from about 40 wt. % to about 70 wt. % of the core.

### Claim 3 (depends on 1)

The implantable device of claim 1, wherein the POE polymer has an acetal monomer content of from about 20 mol. % to about 80 mol. %.

### Claim 4 (depends on 1)

The implantable device of claim 1, wherein the POE polymer has a polyol monomer content of from about 20 mol. % to about 80 mol. %.

### Claim 5 (depends on 4)

The implantable device of claim 4, wherein the polyol monomer content comprises from about 1 mol. % to about 60 mol. % of one or more modified polyols.

### Claim 6 (depends on 1)

The implantable device of claim 1, wherein the POE polymer has a molecular weight of from about 1 kDa to about 100 kDa.

### Claim 7 (depends on 1)

The implantable device of claim 1, wherein the first POE polymer has a Tg of between about 0° C. and 40° C. as determined in accordance with ASTM E1640-18.

### Claim 8 (depends on 1)

The implantable device of claim 1, wherein the one or more therapeutic agents comprise a macromolecular compound having a molecular weight of about 1 kDa or more.

### Claim 9 (depends on 1)

The implantable device of claim 1, wherein the one or more therapeutic agents comprise a protein, peptide, enzyme, antibody, interferon, interleukin, blood factor, vaccine, nucleotide, lipid, or an analogue, derivative, or combination thereof.

### Claim 10 (depends on 1)

The implantable device of claim 1, wherein the one or more therapeutic agents include a tyrosine kinase inhibitor.

### Claim 11 (depends on 1)

The implantable device of claim 1, wherein the one or more therapeutic agents include a VEGF antagonist.

### Claim 12 (depends on 1)

The implantable device of claim 1, wherein the one or more therapeutic agents include a steroidal agent.

### Claim 13 (depends on 1)

The implantable device of claim 1, wherein the device is in the form of a cylinder having a length of from about 1 millimeter to about 250 millimeters and cross-sectional diameter of from about 0.1 millimeters to about 10 millimeters.

### Claim 14 (depends on 1)

The implantable device of claim 1, wherein the device is in the form of a punctal plug.

### Claim 15 (depends on 1)

The implantable device of claim 1, wherein the core is formed from a hot melt extrusion process.

### Claim 16 (depends on 1)

A method for prohibiting and/or treating an ophthalmic disease in a patient in need thereof, the method comprising inserting the device of claim 1 in an eye of a patient.

### Claim 17 (depends on 16)

The method of claim 16, wherein the device is inserted into an anterior segment of the eye.

### Claim 18 (depends on 16)

The method of claim 16, wherein the device is inserted into a posterior segment of the eye.

### Claim 19 (depends on 16)

The method of claim 16, wherein the device is inserted into a vitreous humor of the eye.

### Claim 20 (depends on 16)

The method of claim 16, wherein the device is inserted into a suprachoroidal space of the eye.